Review
Biochemistry & Molecular Biology
Hossein Javid, Fatemeh Attarian, Toktam Saadatmand, Nastaran Rezagholinejad, Ali Mehri, Hamed Amiri, Mehdi Karimi-Shahri
Summary: Breast cancer is the second leading cause of cancer death in women worldwide. Current treatments, such as radiotherapy and chemotherapy, have limited effectiveness and high recurrence rates. Immunotherapy, a novel treatment strategy, may offer potential benefits for cancer patients. This review aims to discuss approved immunotherapy approaches and different strategies for the treatment of breast cancer.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2023)
Review
Oncology
Laura A. Huppert, Veronica Mariotti, A. Jo Chien, Hatem H. Soliman
Summary: Immunotherapy has shown promising results in breast cancer treatment, but there are still many unknowns that need to be explored. Numerous ongoing studies are evaluating the safety and efficacy of immunotherapy in breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Mathematical & Computational Biology
Ana Costa, Nuno Vale
Summary: Breast cancer, a common heterogeneous disease affecting women, can be treated with various strategies such as immunotherapy, nanoparticles, and drug reuse. These approaches can be applied alone or in combination to improve treatment outcomes.
MATHEMATICAL BIOSCIENCES AND ENGINEERING
(2021)
Review
Immunology
Yaping Chen, Xiao Zheng, Changping Wu
Summary: Colorectal cancer has the second highest mortality rate globally, and various treatments have improved patient survival. The emergence of ICIs as a new immunotherapy option for advanced CRC is promising, highlighting the importance of understanding the relationship between tumor immune microenvironment and immunotherapy efficacy for selecting appropriate treatment strategies. This review outlines the latest research progress in the immune microenvironment and immunotherapy strategies for CRC.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Pharmacology & Pharmacy
Sima Singh, Arshid Numan, Balaji Maddiboyina, Saahil Arora, Yassine Riadi, Shadab Md, Nabil A. Alhakamy, Prashant Kesharwani
Summary: Triple-negative breast cancers are a heterogeneous group of breast carcinomas that do not express estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2. Recent trials using immune checkpoint inhibitors for treatment have shown promising early results. This review provides an overview of immunotherapy-based treatments and discusses future opportunities for their use in TNBC.
DRUG DISCOVERY TODAY
(2021)
Review
Oncology
Elena Vagia, Massimo Cristofanilli
Summary: Inflammatory breast cancer remains the most aggressive type of breast cancer, and despite significant progress in refining diagnostic criteria and treatment strategies, outcomes for patients with this subtype are still unsatisfactory. Global efforts are now focused on identifying novel strategies to improve treatment response and prolong survival for metastatic patients.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Hope S. Rugo
Summary: This review article discusses novel treatment strategies for metastatic triple-negative breast cancer (mTNBC), including immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates. The article summarizes important preclinical and clinical data, discusses implications for clinical practice, and highlights future research directions.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Review
Oncology
Jakub Wesolowski, Anna Tankiewicz-Kwedlo, Dariusz Pawlak
Summary: This review summarizes the safety and clinical effectiveness of new biological drugs in stimulating the immune system to fight cancer, particularly in triple-negative breast cancer (TNBC). The introduction of monoclonal antibodies in standard cancer therapies has shown to increase treatment response rates and extend the lives of cancer patients. Recent clinical trials have highlighted the potential of immunotherapy using monoclonal antibodies in difficult-to-treat TNBC, with some trials resulting in the approval of immunotherapeutic agents for TNBC therapy.
Review
Oncology
Jennifer Q. Zhang, George Plitas
Summary: Immunotherapy has become a standard treatment for various types of malignancies, including breast cancer, by enhancing the host antitumor immune response. Recent clinical trials have shown promising results in using checkpoint blockade to mediate clinically significant responses in breast cancer patients.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Lucas E. L. Terceiro, Nnamdi M. Ikeogu, Matheus F. Lima, Chidalu A. Edechi, Barbara E. Nickel, Gabor Fischer, Etienne Leygue, Kirk J. McManus, Yvonne Myal
Summary: Breast cancer is the most common cancer in women, and brain metastasis is a frequent site of spread. Understanding the genetic, epigenetic, angiogenic, and tumor-stroma interactions involved in brain metastasis provides opportunities for potential therapeutic targets. However, the blood-brain barrier poses a challenge to treatment, and current therapies have limited efficacy. Promising new drugs and immunotherapeutic strategies show potential, but are hindered by resistance mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Oluwabukunmi Olajubutu, Omotola D. Ogundipe, Amusa Adebayo, Simeon K. Adesina
Summary: Pancreatic cancer, particularly pancreatic adenocarcinomas, is a fast-growing global threat with limited treatment options. Despite extensive research and development of drug delivery systems using nanotechnology and immunotherapy, there has been limited clinical progress in improving the prognosis of pancreatic cancer. This review highlights the challenge of delivering therapeutics to the pancreas and discusses strategies to minimize side effects and enhance drug treatment efficiency.
Review
Oncology
Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Summary: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, lacks expression of estrogen receptor, progesterone receptor, and HER2. Although chemotherapy is the main treatment for TNBC, its effectiveness is limited. Various targeted therapies, including inhibitors of the PI3K/AKT/mTOR pathway, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates, have emerged. Additionally, immune checkpoint inhibitors such as pembrolizumab, atezolizumab, and durvalumab, are being extensively investigated. This review summarizes recent advances in targeted therapy and immunotherapy in TNBC, aiming to serve as a reference for future development of personalized treatment for TNBC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov, Yongheng Chen
Summary: Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer with a poor prognosis. Current treatment options are limited, but targeted therapies focusing on DNA repair pathways, androgen receptor signaling pathways, kinases, and immunotherapy have shown promise.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Chiara Cilibrasi, Panagiotis Papanastasopoulos, Mark Samuels, Georgios Giamas
Summary: Breast cancer immunotherapy, as an active field of research over the past 50 years, has shown great potential in improving survival rates for patients. Researchers are exploring how breast cancer evades immune destruction and developing new treatment options such as cell therapies, vaccines, checkpoint inhibitors, and oncolytic viruses.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Christiane Matuschek, Danny Jazmati, Edwin Boelke, Balint Tamaskovics, Stefanie Corradini, Wilfried Budach, David Krug, Svjetlana Mohrmann, Eugen Ruckhaeberle, Tanja Fehm, Carolin Nestle Kraemling, Markus Dommach, Jan Haussmann
Summary: In the treatment of breast cancer patients, post-neoadjuvant therapy provides an opportunity to improve patient outcomes by stratifying adjuvant treatment based on tumor response. This individualized approach can both escalate and de-escalate treatment intensity, potentially reducing morbidity. The concept of post-neoadjuvant therapy offers great potential for individualized cancer treatment.